Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Tislelizumab (BGB-A317) in Recurrent Mismatch Repair Deficient Endometrial Cancer and the Effect on the Tumor Microenvironment

NCT04906382 is registered in ClinicalTrials.gov with Floor Backes, MD as lead sponsor.

NCT NCT04906382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Tislelizumab (BGB-A317) in Recurrent Mismatch Repair Deficient Endometrial Cancer and the Effect on the Tumor Microenvironment
Lead sponsor
Floor Backes, MD
Phase
Phase 1
Overall status
Terminated
Start date
July 1, 2021
Completion date
September 1, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lynch syndrome, metastatic endometrial cancer, mismatch repair deficiency, recurrent endometrial cancer, recurrent endometrial carcinoma, recurrent endometrial clear cell adenocarcinoma, recurrent uterine corpus carcinosarcoma